Check-Cap Ltd. (NASDAQ:CHEK) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “Check Cap Ltd. is a medical diagnostics company. The company is engaged in the development of an ingestible imaging capsule for the screening of colorectal cancer. Check Cap Ltd. is based in Mount Carmel, Israel. “

Several other equities analysts have also recently issued reports on the stock. ValuEngine raised shares of Check-Cap from a “sell” rating to a “hold” rating in a research note on Tuesday. Maxim Group reaffirmed a “buy” rating on shares of Check-Cap in a research note on Tuesday, May 30th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $5.00.

Check-Cap (NASDAQ CHEK) traded up 1.09% during mid-day trading on Tuesday, hitting $1.86. 3,980 shares of the stock traded hands. Check-Cap has a 12-month low of $1.08 and a 12-month high of $3.42. The firm’s market cap is $29.07 million. The stock has a 50 day moving average price of $1.94 and a 200 day moving average price of $2.17.

ILLEGAL ACTIVITY WARNING: “Zacks Investment Research Lowers Check-Cap Ltd. (CHEK) to Hold” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at

A hedge fund recently raised its stake in Check-Cap stock. Knott David M increased its position in shares of Check-Cap Ltd. (NASDAQ:CHEK) by 1.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 162,871 shares of the medical research company’s stock after buying an additional 3,000 shares during the period. Knott David M owned about 1.05% of Check-Cap worth $349,000 as of its most recent SEC filing. Institutional investors own 13.35% of the company’s stock.

About Check-Cap

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

Get a free copy of the Zacks research report on Check-Cap (CHEK)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Check-Cap Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap Ltd. and related companies with's FREE daily email newsletter.